原发性肝癌患者血清可溶性白介素2受体检测及其临床意义  

Clinical Significance of Soluble Interleukin-2 Receptor in Primary Hepatocellular Carcinoma

作　　者：朱瑞龙[1] 陈士葆[1] 张兴荣[1] 沈健伟[1] 杜学礼 郝吉生 

机构地区：[1]第二军医大学附属长征医院消化内科,上海市宝山区罗店医院内科,国防科工委江阴基地515医院

出　　处：《中国肿瘤临床》1996年第1期18-20,共3页Chinese Journal of Clinical Oncology

摘　　要：应用夹心酶联免疫吸附法（ＥＬＩＳＡ）检测４５例原发性肝癌（ＰＨＣ）患者及４２例健康成人的血清可溶性白介素２受体（ｓＴＬ－２Ｒ）水平，结果显示ＰＨＣ患者ｓＩＬ－２Ｒ水平较健康成人明显增高（Ｐ＜０．０１），其升高幅度与肿瘤体积大小有关（Ｐ＜０．０５），而与ＡＦＰ及ＨＢｓＡｇ阳性与否无关（Ｐ＞０．０５）。故ＰＨＣ者测定血清ｓＩＬ－２Ｒ不仅能了解肿瘤患者的机体免疫功能状态，且在一定程度上能对疾病的严重程度、疗效及判断预后作出评估。The level of soluble intereukin-2 receptor(sIL-2R) was measured by an enzyme-linked immunosorbent assay in 45 cases of primary hepatocellular carcinoma(PHC) and 42 healthy adults served as control.The results showed that serum sIL-2R level in PHC group(1103. 8±388. 7u/ml) was higher than that of healthy control group(460.2±140.2u/ml)(P<0.01).The serum sIL-2R in patients with PHC was significantly correlated with the size of neoplasm(P<0.05),but not with AFP level or whether the HBsAg was positive or not.It is concluded that the serum sIL-2R level may reflect the human immunity function,degree of me disease, and can be used to evaluate the therapeutic effect.

关 键 词：肝肿瘤 SIL-2R ELISA 诊断 

分 类 号：R735.704[医药卫生—肿瘤]